Iterative Upgrading of Small Molecular Tyrosine Kinase Inhibitors for EGFR Mutation in NSCLC: Necessity and...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Molecular targeted therapy presents advantages over conventional chemotherapy in terms of reduced adverse effects and improved administration convenience.
• Advances in sequencing technology and molecular biology research have identified numerous therapeutic targets in non-small cell lung cancer (NSCLC).
• Epidermal growth factor receptor (EGFR) mutations are the most prevalent driver mutations in NSCLC, particularly in Asian populations, presenting significant therapeutic opportunities.

Purpose of the Study:

• To review the clinical indications of approved small molecular kinase inhibitors for EGFR mutation-positive NSCLC.
• To explore the mechanisms of acquired drug resistance and outline corresponding therapeutic strategies.
• To discuss the principles of rational molecular design and advancements in next-generation EGFR inhibitors.

Main Methods:

• Comprehensive literature review of approved and investigational targeted therapies for EGFR-mutated NSCLC.
• Analysis of molecular mechanisms underlying resistance to EGFR inhibitors.
• Examination of drug development pipelines and emerging therapeutic strategies.

Main Results:

• Several targeted agents for EGFR mutations are approved or in clinical trials, demonstrating efficacy in specific NSCLC patient populations.
• Understanding resistance mechanisms is crucial for developing effective sequential or combination therapies.
• Next-generation inhibitors are being developed to overcome resistance and broaden treatment applicability.

Conclusions:

• Targeted therapy, particularly for EGFR mutations, represents a paradigm shift in NSCLC treatment, offering personalized and effective options.
• Continued research into resistance mechanisms and novel inhibitor development is essential for improving long-term patient outcomes in EGFR-mutated NSCLC.
• Precision medicine approaches, guided by molecular profiling, are key to optimizing treatment selection and efficacy.